The report forecasts the global next-generation biologics market to grow at a CAGR of 14.42% during the period 2016-2020.
The report covers the present scenario and the growth prospects of the global next-generation biologics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of next-generation biologics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market during the forecast period.
The use of regenerative medicine is an emerging treatment option for the treatment of various disorders such as musculoskeletal, CNS, metabolic and cardiovascular disorders, oncology, and dermatology. These regenerative medicines help in the healing process by replacement or regeneration of the human cells, tissues or organs, and thus assist in establishing the normal function. The various regenerative techniques include cell therapy, growth factor therapy, and the use of matrices such as fibrin, collagen, urinary bladder matrix, hyaluronic acid, and others. Apart from these companies, various research organizations such as Mayo Clinic and Center for Regenerative Medicine are also engaged in the development of regenerative medicines.
According to the report, the US FDA's Office of Orphan Products Development (OOPD) aims to develop and evaluate drugs and biologics that effectively treat and diagnose rare diseases or conditions, and provides incentives to companies that develop drugs for rare disorders. It also grants orphan status to drugs and biologics proven to be effective and safe in treating rare diseases. The Orphan Products Grants Program (OPGP) funds clinical research tests to check the efficacy and safety of drugs and biologics.
Further, the report states that unlike small molecule drugs, biologics are prepared from living organisms. Hence, the manufacturing process involved is very complex and time-consuming. The process involves steps such as fermentation, clarification, separation, and purification.
- F. Hofmann-La Roche
- Novo Nordisk
- Takeda Pharmaceuticals
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Market landscape
Part 06: Market segmentation by application
Part 07: Geographical segmentation
Part 08: Market drivers
Part 09: Impact of drivers
Part 10: Market challenges
Part 11: Impact of drivers and challenges
Part 12: Market trends
Part 13: Vendor landscape
Part 14: Key vendor analysis
Part 15: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/b97vv2/global
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-next-generation-biologics-market-growth-of-14-2016-2020---complexities-in-manufacturing-of-biologics-hinder-growth---research-and-markets-300379716.html
SOURCE Research and Markets